Published ahead of print on March 31, 2005, doi:10.1165/rcmb.2004-0010OC
American Journal of Respiratory Cell and Molecular Biology. Vol. 33, pp. 22-31, 2005
© 2005 American Thoracic Society DOI: 10.1165/rcmb.2004-0010OC
-Galactosylceramide, a Ligand of Natural Killer T Cells, Inhibits Allergic Airway Inflammation
Hiroyuki Matsuda,
Takafumi Suda,
Jun Sato,
Toshi Nagata,
Yukio Koide,
Kingo Chida and
Hirotoshi Nakamura
Second Division, Department of Internal Medicine, and Department of Microbiology and Immunology, Hamamatsu University School of Medicine, Hamamatsu, Japan
Correspondence and requests for reprints should be addressed to Takafumi Suda, M.D., Ph.D., Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, Shizuoka, 431-3192 Japan. E-mail: suda{at}hama-med.ac.jp
-Galactosylceramide ( -GalCer) is a specific ligand of natural killer T cells (NKT cells) that regulates the immune responses such as tumor rejection and autoimmunity by producing interferon (IFN)- and interleukin (IL)-4. However, it has not been determined whether -GalCeractivated NKT cells modulate allergic inflammation. Because -GalCer induces a large amount of IFN- production by NKT cells, we hypothesized that an in vivo administration of -GalCer could inhibit allergic airway inflammation in mice. Strikingly, a single intraperitoneal injection of -GalCer almost completely abrogated an infiltrate with eosinophils in the lung tissue as well as in the bronchoalveolar lavage. This inhibition of allergic inflammation was associated with a significant decrease in the levels of IL-4, IL-5, and IL-13 in bronchoalveolar lavage fluid and in the number of goblet cells. In addition, this ligand significantly inhibited airway hyperresponsiveness to inhaled methacholine and raised the serum levels of ovalbumin-specific IgG2a with a decrease in those of ovalbumin-specific IgE. In IFN- knockout mice, however, -GalCer failed to exert such inhibitory effects in this asthma model. These results indicate that -GalCer prevents allergic airway inflammation possibly through IFN- production by ligand-activated NKT cells, suggesting the potential therapeutic application of -GalCer in asthma.
Key Words: asthma natural killer T cell -galactosylceramide interferon-
This article has been cited by other articles:

|
 |

|
 |
 
D.-H. Kim, W.-S. Chang, Y.-S. Lee, K.-A Lee, Y.-K. Kim, B. S. Kwon, and C.-Y. Kang
4-1BB Engagement Costimulates NKT Cell Activation and Exacerbates NKT Cell Ligand-Induced Airway Hyperresponsiveness and Inflammation
J. Immunol.,
February 15, 2008;
180(4):
2062 - 2068.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Barrera, F. Mendoza, J. Zuniga, A. Estrada, A. C. Zamora, E. I. Melendro, R. Ramirez, A. Pardo, and M. Selman
Functional Diversity of T-Cell Subpopulations in Subacute and Chronic Hypersensitivity Pneumonitis
Am. J. Respir. Crit. Care Med.,
January 1, 2008;
177(1):
44 - 55.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Jin, N. Miyahara, C. L. Roark, J. D. French, M. K. Aydintug, J. L. Matsuda, L. Gapin, R. L. O'Brien, E. W. Gelfand, and W. K. Born
Airway Hyperresponsiveness through Synergy of {gamma}{delta} T Cells and NKT Cells
J. Immunol.,
September 1, 2007;
179(5):
2961 - 2968.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. B. Kay
Natural killer T cells and asthma.
N. Engl. J. Med.,
March 16, 2006;
354(11):
1186 - 1188.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. H. Meyer, S. Goya, O. Akbari, G. J. Berry, P. B. Savage, M. Kronenberg, T. Nakayama, R. H. DeKruyff, and D. T. Umetsu
Glycolipid activation of invariant T cell receptor+ NK T cells is sufficient to induce airway hyperreactivity independent of conventional CD4+ T cells
PNAS,
February 21, 2006;
103(8):
2782 - 2787.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2005 American Thoracic Society.
|
|
|